BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 4,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $17.65, for a total transaction of $70,600.00. Following the sale, the insider now owns 65,843 shares in the company, valued at $1,162,128.95. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Sarah Aebersold also recently made the following trade(s):
- On Wednesday, February 21st, Sarah Aebersold sold 58 shares of BioLife Solutions stock. The stock was sold at an average price of $17.35, for a total transaction of $1,006.30.
- On Tuesday, January 23rd, Sarah Aebersold sold 336 shares of BioLife Solutions stock. The stock was sold at an average price of $17.11, for a total transaction of $5,748.96.
BioLife Solutions Stock Down 1.6 %
Shares of NASDAQ BLFS opened at $17.32 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.83 and a current ratio of 2.86. BioLife Solutions, Inc. has a 52-week low of $8.92 and a 52-week high of $24.50. The company's 50 day moving average price is $17.73 and its 200-day moving average price is $15.07. The company has a market capitalization of $784.60 million, a P/E ratio of -11.39 and a beta of 1.67.
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Equities analysts forecast that BioLife Solutions, Inc. will post -0.35 earnings per share for the current year.
Institutional Trading of BioLife Solutions
Several institutional investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new position in shares of BioLife Solutions in the first quarter worth approximately $36,000. Nisa Investment Advisors LLC lifted its position in BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 1,020 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in BioLife Solutions during the first quarter valued at approximately $36,000. Lazard Asset Management LLC bought a new stake in BioLife Solutions during the first quarter valued at approximately $45,000. Finally, GAMMA Investing LLC bought a new stake in BioLife Solutions during the fourth quarter valued at approximately $41,000. Institutional investors own 93.24% of the company's stock.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
